DCLK1 and pancreatic neoplasm: demonstrated that LRRK2‐IN‐1 (a nonspecific selective inhibitor of DCLK1) enhanced the cytotoxic effects of gemcitabine via suppressing Chk1 phosphorylation in pancreatic cancer cells.